Literature DB >> 8611427

Characterisation of circulating chromogranin A in human cancer patients.

A Corti1, A Gasparri, F X Chen, M Pelagi, A Brandazza, A Sidoli, A G Siccardi.   

Abstract

The structure of circulating chromogranin A (CgA) of phaeochromocytoma patients was characterised and compared with that of CgA extracted from tumours. Size exclusion chromatography experiments provided evidence that CgA is present in the blood of different patients, as well as in tumour extracts, as multiple forms having different hydrodynamic sizes of 600 kDa (CgA-I), 100 kDa (CgA-II) and 55 kDA (CgA-III). The amount of each CgA form as a proportion of the total antigenic material was different in different patients. Western blot analysis of chromatographic fractions indicated that these forms are made up by polypeptides of similar molecular weight (about 60-70 kDa). All CgA forms express the epitopes recognised by two monoclonal antibodies (A11 and B4E11), directed against residues 68-70 and 81-90 of human CgA. However, their relative immunoreactivity was markedly different. No evidence for the presence of multimeric complexes in the CgA-I fraction was obtained by various immunological and biochemical methods. These results suggest that circulating CgA in phaeochromocytoma patients consists of at least three forms that appear to be made up by polypeptides with similar molecular weight and different hydrodynamic properties and immunoreactivity. We hypothesise that different conformations and shapes contribute to the heterogeneity of circulating CgA.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8611427      PMCID: PMC2075816          DOI: 10.1038/bjc.1996.183

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  29 in total

1.  Chromogranin A and B and secretogranin II in bronchial and intestinal carcinoids.

Authors:  R Weiler; H Feichtinger; K W Schmid; R Fischer-Colbrie; L Grimelius; B Cedermark; M Papotti; G Bussolati; H Winkler
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1987

2.  The primary structure of human chromogranin A and pancreastatin.

Authors:  D S Konecki; U M Benedum; H H Gerdes; W B Huttner
Journal:  J Biol Chem       Date:  1987-12-15       Impact factor: 5.157

3.  How sensitive and specific is measurement of plasma chromogranin A for the diagnosis of neuroendocrine neoplasia?

Authors:  D T O'Connor; L J Deftos
Journal:  Ann N Y Acad Sci       Date:  1987       Impact factor: 5.691

4.  Elevated serum chromogranin A concentrations in small-cell lung carcinoma.

Authors:  R E Sobol; D T O'Connor; J Addison; K Suchocki; I Royston; L J Deftos
Journal:  Ann Intern Med       Date:  1986-11       Impact factor: 25.391

5.  Secretion of chromogranin A by peptide-producing endocrine neoplasms.

Authors:  D T O'Connor; L J Deftos
Journal:  N Engl J Med       Date:  1986-05-01       Impact factor: 91.245

6.  Chromogranin A, the major catecholamine storage vesicle soluble protein. Multiple size forms, subcellular storage, and regional distribution in chromaffin and nervous tissue elucidated by radioimmunoassay.

Authors:  D T O'Connor; R P Frigon
Journal:  J Biol Chem       Date:  1984-03-10       Impact factor: 5.157

7.  Isolation and characterization of chromogranins A, B, and C from bovine chromaffin granules and a rat pheochromocytoma.

Authors:  R Fischer-Colbrie; M Schober
Journal:  J Neurochem       Date:  1987-01       Impact factor: 5.372

8.  Demonstration of Chromogranin A in human neuroendocrine cell lines by immunohistology and immunoassay.

Authors:  L J Deftos; R I Linnoila; D N Carney; D W Burton; S S Leong; D T O'Connor; S S Murray; A F Gazdar
Journal:  Cancer       Date:  1988-07-01       Impact factor: 6.860

9.  Antigenic regions of human chromogranin A and their topographic relationships with structural/functional domains.

Authors:  A Corti; R Longhi; A Gasparri; F Chen; M Pelagi; A G Siccardi
Journal:  Eur J Biochem       Date:  1996-01-15

10.  The primary structure of human secretogranin I (chromogranin B): comparison with chromogranin A reveals homologous terminal domains and a large intervening variable region.

Authors:  U M Benedum; A Lamouroux; D S Konecki; P Rosa; A Hille; P A Baeuerle; R Frank; F Lottspeich; J Mallet; W B Huttner
Journal:  EMBO J       Date:  1987-05       Impact factor: 11.598

View more
  14 in total

1.  Characterization of serum and urinary chromogranin A by size exclusion chromatography: impact on calibrator selection and urinary assay.

Authors:  K C Tsao; G H Liu; P Y Chang; C N Lin; T L Wu; C F Sun; J T Wu
Journal:  J Clin Lab Anal       Date:  2001       Impact factor: 2.352

Review 2.  Chromogranin A and derived peptides in health and disease.

Authors:  Y Peng Loh; Yong Cheng; Sushil K Mahata; Angelo Corti; Bruno Tota
Journal:  J Mol Neurosci       Date:  2012-03-03       Impact factor: 3.444

Review 3.  Chromogranin A and the tumor microenvironment.

Authors:  Angelo Corti
Journal:  Cell Mol Neurobiol       Date:  2010-11-16       Impact factor: 5.046

4.  Long human CHGA flanking chromosome 14 sequence required for optimal BAC transgenic "rescue" of disease phenotypes in the mouse Chga knockout.

Authors:  Sucheta M Vaingankar; Ying Li; Angelo Corti; Nilima Biswas; Jiaur Gayen; Daniel T O'Connor; Sushil K Mahata
Journal:  Physiol Genomics       Date:  2009-12-15       Impact factor: 3.107

Review 5.  Chromogranin A: a novel susceptibility gene for essential hypertension.

Authors:  Bhavani S Sahu; Parshuram J Sonawane; Nitish R Mahapatra
Journal:  Cell Mol Life Sci       Date:  2009-11-27       Impact factor: 9.261

6.  A new human chromogranin 'A' immunoradiometric assay for the diagnosis of neuroendocrine tumours.

Authors:  G P Bernini; A Moretti; M Ferdeghini; S Ricci; C Letizia; E D'Erasmo; G F Argenio; A Salvetti
Journal:  Br J Cancer       Date:  2001-03-02       Impact factor: 7.640

7.  A new human chromogranin A (CgA) immunoradiometric assay involving monoclonal antibodies raised against the unprocessed central domain (145-245).

Authors:  F Degorce; Y Goumon; L Jacquemart; C Vidaud; L Bellanger; D Pons-Anicet; P Seguin; M H Metz-Boutigue; D Aunis
Journal:  Br J Cancer       Date:  1999-01       Impact factor: 7.640

8.  Chromogranin A pathway: from pathogenic molecule to renal disease.

Authors:  Saiful A Mir; Nilima Biswas; Wai Cheung; Ji Wan; Nicholas Webster; Etienne Macedo; Daniel T O'Connor; Sucheta M Vaingankar
Journal:  J Hypertens       Date:  2020-03       Impact factor: 4.776

9.  Chromogranin A: Novel biomarker between periodontal disease and psychosocial stress.

Authors:  Arunima Padmakumar Reshma; Rajeev Arunachalam; Jayakumar Kochu Pillai; Sarath Babu Kurra; Vini K Varkey; Mohanraj J Prince
Journal:  J Indian Soc Periodontol       Date:  2013-03

Review 10.  The surging role of Chromogranin A in cardiovascular homeostasis.

Authors:  Bruno Tota; Tommaso Angelone; Maria C Cerra
Journal:  Front Chem       Date:  2014-08-14       Impact factor: 5.221

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.